Biodistribution and dosimetry of 195mPt-cisplatin in normal volunteers: Imaging agent for single photon emission computed tomography;Biodistribution und dosimetrie von 195mPt-cisplatin bei gesunden probanden bildgebendes radionuklid für die einzelphotonen-emissionscomputertomographie

NuklearMedizin

Volumn 52, Issue 6, 2013, Pages 222-227

  Sathekge, Mike ^a   Wagener, J ^b   Smith, S V ^c,d   Soni, N ^a   Marjanovic Painter, B ^b   Zinn, C ^a   Van de Wiele, C ^e   D'Asseler, Y ^e   Perkins, G ^c   Zeevaart, J R ^f  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b Radiochemistry   (South Africa)

^c AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^d BROOKHAVEN NATIONAL LABORATORY   (United States)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f NORTH WEST UNIVERSITY   (South Africa)

Author keywords

195mPt cisplatin; Biodistribution; Normal volunteers

Indexed keywords

CISPLATIN PLATINUM 195 M; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CISPLATIN; PLATINUM;

ARTICLE; BODY DISTRIBUTION; DOSIMETRY; HALF LIFE TIME; HUMAN; INFORMATION PROCESSING; KIDNEY CLEARANCE; LIVER TOXICITY; NAUSEA AND VOMITING; NEPHROTOXICITY; NORMAL HUMAN; OTOTOXICITY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR RESISTANCE; URINALYSIS; WHOLE BODY SCINTISCANNING; 195MPT-CISPLATIN; ADULT; ANTIBODY SPECIFICITY; BIODISTRIBUTION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METHODOLOGY; RADIATION DOSE; REFERENCE VALUE; TISSUE DISTRIBUTION; WHOLE BODY COUNTING; WHOLE BODY IMAGING;

195MPT-CISPLATIN; BIODISTRIBUTION; NORMAL VOLUNTEERS;

ADULT; CISPLATIN; HEALTHY VOLUNTEERS; HUMANS; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; PLATINUM; RADIATION DOSAGE; RADIOISOTOPES; REFERENCE VALUES; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE BODY IMAGING; WHOLE-BODY COUNTING;

EID: 84890099312     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0599-13-06     Document Type: Article

References (25)

1. Andrews PA, Howell SB. Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 1990; 2: 35-42.
2. 195mPt-cisplatin. Appl Radiat Isot 1996; 51: 581-586.
3. Barnham KJ, Djuran MI, Murdoch PS et al. Ringopened adducts of the anticancer drug carboplatin with sulfur amino acids. Inorg Chem 1996; 35: 1065-1072.
4. 123I)FP-CIT: a potent radioligand for imaging of dopamine transporters. Eur J Nucl Med 1998; 25: 24-30.
5. Chu G. Cellular responses to cisplatin. J Bio Chem 1994; 269: 787-790.
6. De Conti RC, Toftness BR, Lange RC, Creasey WA. Clinical and pharmacological studies with cisdiamminedichloroplatinum. Cancer Res 1973; 33: 1310-1315.
7. De Lange SM, van Groeningen CJ, Kroep JR et al. Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer. Ann Oncol 2004; 15: 484-488.
8. Eastman A. In: Lippert B (ed). Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Helvetica Chimica Acta: Zurich; Wiley-VCH: Weinheim, Germany, 1999; 111-134.
9. Eustace P. History and development of cisplatin in the management of malignant disease. Cancer Nurs 1980; 3: 373-378.
10. Iosilevsky G, Israel O, Frenkel A et al. A practical SPECT technique for quantitation of drug delivery to human tumors and organ absorbed radiation dose. Semin Nucl Med 1989; 19: 33-46.
11. International Commission on Radiobiological Protection. Limits for Intakes of Radionuclides by Workers: ICRP Publication 30. New York, NY: Pergamon Press 1979.
12. Jamieson E R, Lippard S J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999; 99: 2467-2498.
13. Kelland LR. In: Lippert B (ed). Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug. Helvetica Chimica Acta, Zurich; Wiley-VCH: Weinheim, Germany, 1999. 497-521.
14. Kratz F. In: Keppler BK (ed). Metal Complexes in Cancer Chemotherapy. VCH: Weinheim, Germany, 1993: 391-429.
15. Lagasse LD, Pretorius RG, Petrilli ES et al. The metabolism of cis-dichlorodiammineplatinum (II): distribution, clearance, and toxicity. Am J Obstet Gynecol 1981; 139: 791-798.
16. 195mPt. J Nucl Med 1972; 14: 191-195.
17. Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur J Cancer 1998; 34: 1522-1534.
18. Osman AM, El-Sayed E. M, El-Demersash E et al. Prevention of cisplatin-induced nephrotoxicity by methimazole. Pharmacol Res 2000; 41: 115-121.
19. Rosenberg B. Fundamental studies of cisplatin. Cancer 1985; 55: 2303-2316.
20. Rosenberg B, Van Camp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumor agents. Nature 1969; 222: 385-386.
21. 195mPt-cisplatin in humans. Cancer Res 1989; 49: 1877-1881.
22. 195mPt-cisdichlorodi-ammineplatinum (II) in man. J Nucl Med 1974; 15: 349-351.
23. Smith SV, inventor; ANSTO, assignee. Methods of synthesis and use of radiolabelled platinum chemotherapeutic agents. World Intellectual Property Organization patent WO 01/70755 A1. 2001 Sept 27.
24. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005; 46:1023-1027.
25. Zicca A, Cafaggi S, Mariggió MA et al. Reduction of cisplatin hepatoxicity by procainamide hydrochloride in rats. Eur J Pharmacol 2002; 442: 265-272.